D. E. Shaw & Co. Inc. Purchases 40,001 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

D. E. Shaw & Co. Inc. boosted its stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 54.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 112,841 shares of the company's stock after purchasing an additional 40,001 shares during the period. D. E. Shaw & Co. Inc. owned about 0.15% of Nurix Therapeutics worth $2,126,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Cubist Systematic Strategies LLC bought a new position in shares of Nurix Therapeutics in the fourth quarter worth approximately $2,337,000. Brevan Howard Capital Management LP bought a new stake in Nurix Therapeutics in the 4th quarter worth $405,000. Bank of America Corp DE increased its position in shares of Nurix Therapeutics by 9.3% in the fourth quarter. Bank of America Corp DE now owns 150,935 shares of the company's stock valued at $2,844,000 after acquiring an additional 12,811 shares during the period. BNP Paribas Financial Markets purchased a new position in shares of Nurix Therapeutics in the fourth quarter valued at about $164,000. Finally, Ameriprise Financial Inc. raised its stake in shares of Nurix Therapeutics by 111.1% during the fourth quarter. Ameriprise Financial Inc. now owns 32,152 shares of the company's stock valued at $606,000 after acquiring an additional 16,921 shares during the last quarter.

Insider Buying and Selling

In other Nurix Therapeutics news, insider Gwenn Hansen sold 3,377 shares of Nurix Therapeutics stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $11.50, for a total value of $38,835.50. Following the completion of the sale, the insider now owns 61,516 shares of the company's stock, valued at approximately $707,434. This trade represents a 5.20% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Houte Hans Van sold 5,825 shares of the business's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $14.49, for a total value of $84,404.25. Following the completion of the transaction, the chief financial officer now owns 33,724 shares of the company's stock, valued at $488,660.76. This represents a 14.73% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 17,838 shares of company stock worth $221,500 in the last quarter. Corporate insiders own 7.40% of the company's stock.

Nurix Therapeutics Stock Performance

Shares of NRIX traded down $0.27 during mid-day trading on Monday, reaching $9.72. The company had a trading volume of 401,505 shares, compared to its average volume of 873,228. Nurix Therapeutics, Inc. has a 52 week low of $8.18 and a 52 week high of $29.56. The company has a market capitalization of $741.01 million, a price-to-earnings ratio of -3.36 and a beta of 2.23. The firm has a 50-day moving average price of $10.59 and a 200 day moving average price of $16.12.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last released its earnings results on Tuesday, April 8th. The company reported ($0.67) EPS for the quarter, topping the consensus estimate of ($0.72) by $0.05. Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. The business had revenue of $18.45 million for the quarter, compared to the consensus estimate of $12.78 million. During the same period in the previous year, the company posted ($0.76) earnings per share. As a group, research analysts forecast that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Stifel Nicolaus cut their target price on Nurix Therapeutics from $36.00 to $35.00 and set a "buy" rating on the stock in a research note on Wednesday, April 9th. HC Wainwright reiterated a "buy" rating and issued a $36.00 price objective on shares of Nurix Therapeutics in a report on Wednesday, April 2nd. Wall Street Zen cut Nurix Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday. JPMorgan Chase & Co. decreased their target price on Nurix Therapeutics from $31.00 to $30.00 and set an "overweight" rating for the company in a report on Wednesday, January 29th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $27.00 price target on shares of Nurix Therapeutics in a research note on Tuesday, April 29th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat, Nurix Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $30.44.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.